Correlation between NGS panel-based mutation results and clinical information in colorectal cancer patients

Le résumé fourni par la source

Early mutation identification guides patients with colorectal cancer (CRC) toward targeted therapies. In the present study, 414 patients with CRC were enrolled, and amplicon-based targeted next-generation sequencing (NGS) was then performed to detect genomic alterations within the 73 cancer-related genes in the OncoAim panel. The overall mutation rate was 91.5 % (379/414). Gene mutations were detected in 38/73 genes tested. The most frequently mutated genes were TP53 (60.9 %), KRAS (46.6 %), APC (30.4 %), PIK3CA (15.9 %), FBXW7 (8.2 %), SMAD4 (6.8 %), BRAF (6.5 %), and NRAS (3.9 %). Compared with the wild type, TP53 mutations were associated with low microsatellite instability/microsatellite stability (MSI-L/MSS) ( P = 0.007), tumor location ( P = 0.043), and histological grade ( P = 0.0009); KRAS mutations were associated with female gender ( P = 0.026), distant metastasis ( P = 0.023), TNM stage ( P = 0.013), and histological grade ( P = 0.004); APC mutations were associated with patients <64 years of age at diagnosis ( P = 0.04); PIK3CA mutations were associated with tumor location ( P = 4.97e-06) and female gender ( P = 0.018); SMAD4 mutations were associated with tumor location ( P = 0.033); BRAF mutations were associated with high MSI (MSI-H; P = 6.968e-07), tumor location ( P = 1.58e-06), and histological grade ( P = 0.04). Mutations in 164 individuals were found to be pathogenic or likely pathogenic. A total of 26 patients harbored MSI-H tumors and they all had at least one detected gene mutation. Mutated genes were enriched in signaling pathways associated with CRC. The present findings have important implications for improving the personalized treatment of patients with CRC in China.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.